Skip to main content

Table 2 Clinical characteristics of CSR OMG and non-CSR OMG

From: Thymectomy in ocular myasthenia gravis—prognosis and risk factors analysis

  Overall (52) CSR OMG (16) Non-CSR OMG (36) p value
Gender, n (%)     0.282
 Male 22 (42.3%) 5 (31.3%) 17 (47.2%)  
 Female 30 (57.7%) 11 (68.8%) 19 (52.8%)  
Onset age (years), mean ± SD 54.7 ± 13.5 48.3 ± 13.7 57.5 ± 12.6 0.022*
Onset age (years), n (%)     0.016*
 ≤ 60 33 (63.5%) 14 (87.5%) 19 (52.8%)  
 > 60 19 (36.5%) 2 (12.5%) 17 (47.2%)  
Ptosis, n (%)     0.765c
 Left 18 (34.6%) 6 (37.5%) 12 (33.3%)  
 Right 14 (26.9%) 5 (31.3%) 9 (25.0%)  
 Bilateral 20 (38.5%) 5 (31.3%) 15 (41.7%)  
Diplopia ( +), n (%) 21 (40.4%) 9 (56.3%) 12 (33.3%) 0.120
Anti-AchR Ab ( +), n (%) 34 (65.4%) 7 (43.8%) 27 (75.0%) 0.029*
RNS ( +), n (%) 23 (44.2%) 4 (25.0%) 19 (52.8%) 0.063
Disease duration before surgery (weeks), mean ± SD 19.4 ± 46.6 8.6 ± 9.9 24.1 ± 55.2 0.111
Surgical approach, n (%)     0.056c
 R/L-VATS 22 (42.3%) 10 (62.5%) 12 (33.3%)  
 TS 8 (15.4%) 3 (18.8%) 5 (13.9%)  
 Sub-xiphoid 22 (42.3%) 3 (18.8%) 19 (52.8%)  
Tumor location, n (%)     0.488b
 Left 19 (48.7%) 4 (40.0%) 15 (51.7%)  
 Right 18 (46.2%) 5 (50.0%) 13 (44.8%)  
 L + Ra 2 (5.1%) 1 (10%) 1 (3.4%)  
Maximum diameter (cm) mean ± SD 3.8 ± 1.6 3.6 ± 2.2 3.9 ± 1.4 0.592
Median size (cm) mean ± SD 3.1 ± 1.3 3.0 ± 1.7 3.1 ± 1.1 0.739
Thymoma histotype + hyperplasia, n (%)     0.330b
 Thymoma     
  AB 9 (17.3%) 1 (6.3%) 8 (22.2%)  
  B1 4 (7.7%) 2 (12.5%) 2 (5.6%)  
  B2 18 (34.6%) 4 (25.0%) 14 (38.9%)  
  B3 8 (15.4%) 3 (18.8%) 5 (13.9%)  
 Hyperplasia 13 (25.0%) 6 (37.5%) 7 (19.4%)  
Thymoma Stage + hyperplasia, n (%)     0.086b
 Thymoma     
  I 9 (17.3%) 5 (31.3%) 4 (11.1%)  
 IIa 12 (23.1%) 1 (6.3%) 11 (30.6%)  
 IIb 12 (23.1%) 2 (12.5%) 10 (27.8%)  
 III 6 (11.5%) 2 (12.5%) 4 (11.1%)  
 Hyperplasia 13 (25.0%) 6 (37.5%) 7 (19.4%)  
 Hyperplasia: thymoma 13:39 6:10 7:29 0.298
 Hyperplasia + I: II + III 22:30 11:5 11:25 0.010*
NTOMG, n (%)     0.592b
 Early-onset (age ≤ 50) 7 (13.5%) 4 (25%) 3 (8.3%)  
 Late-onset (age > 50) 6 (11.5%) 2 (12.5%) 4 (11.1%)  
Post-operative prednisone ( +), n (%) 18 (34.6%) 5 (31.3%) 13 (36.1%) 0.734
Post-operative follow-up duration (months), mean ± SD 60.5 ± 27.7 78.3 ± 28.6 58.3 ± 25.4 0.015*
  1. Values in boldface as well as * indicate statistically significant
  2. CSR complete stable remission, OMG ocular myasthenia gravis, NTOMG non-thymomatous OMG, AChR-ab anti-acetylcholine receptor antibody, RNS repetitive nerve stimulation, R/L-VATS right/left-video assisted thoracic surgery, TS trans-sternal
  3. *Statistically significant
  4. aTumor boundary exceeds both sides of sternal border
  5. bFisher exact test
  6. cLikelihood Ratio test